• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
Jul 18, 2019 8:30am EDT

VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

Jul 10, 2019 8:30am EDT

VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

May 08, 2019 4:05pm EDT

VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

May 07, 2019 8:30am EDT

VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

May 06, 2019 4:05pm EDT

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

Apr 09, 2019 5:17pm EDT

VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

Apr 09, 2019 8:30am EDT

VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

Apr 03, 2019 8:30am EDT

VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

Mar 28, 2019 8:30am EDT

VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

Mar 25, 2019 8:40am EDT

VolitionRx Limited to Present at Conferences in March & April 2019

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.